Eli Lilly的新药丸Orforglipron在降低血糖和帮助体重减退、挑战GLP-1注射方面很有前途。 Eli Lilly's new pill, Orforglipron, shows promise in lowering blood sugar and aiding weight loss, challenging GLP-1 injections.

Eli Lilly成功地完成了对Orforglipron的第三阶段研究,Orforglipron是一种日间避孕药,可以降低血糖,有助于减肥,有可能取代像Ozempic这样的昂贵的GLP-1注射。 Eli Lilly has successfully completed a Phase 3 study for Orforglipron, a daily pill that may lower blood sugar and aid in weight loss, potentially replacing costly GLP-1 injections like Ozempic. 在40周内,参加者平均损失9.7至16磅,在安慰剂上的人平均损失2.9磅。 Participants lost an average of 9.7 to 16 pounds over 40 weeks, with those on a placebo losing 2.9 pounds. 该药物与标准的GLP-1药物表现出类似的安全和功效,具有共同副作用,包括胃肠问题和疲劳。 The drug showed similar safety and efficacy to standard GLP-1 medications, with common side effects including gastrointestinal issues and tiredness. 参加者还平均将A1C水平降低1.3%至1.6%。 Participants also lowered their A1C levels by an average of 1.3% to 1.6%.